Skip to main content
SpringerLink
Log in

Bevacizumab/lapatinib/trastuzumab

Diarrhoea and mucositis: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Falchook GS, et al. Human epidermal receptor 2-amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head and Neck 36: E25-E27, No. 3, Mar 2014. Available from: URL: http://doi.org/10.1002/hed.23429 - USA

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bevacizumab/lapatinib/trastuzumab. Reactions Weekly 1503, 10 (2014). https://doi.org/10.1007/s40278-014-1058-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-014-1058-4

Search

Navigation